EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non–Small Cell Lung Cancer: A Case Report

Huaiyu Wang, Zaiwen Fan, Xiaoming Yang, Qing Wu, Suxin Jiang, Jingna Zhu, Jie Liu, Chuanhong Zhou, Yinghui Liu, Xia You, Yong Han

The Oncologist · 2024

DOI: 10.1093/oncolo/oyad339 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Oncologist, 2024. Verfasst von Huaiyu Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Surgery Department, Air Force Medical Center, PLA, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Protein Kinase Inhibitors, ErbB Receptors, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wu Jieping Medical Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sequential regimens in patients with epidermal growth factor receptor (EGFR) mutation-positive non–small cell lung cancer (NSCLC) can overcome tyrosine kinase inhibitor (TKI) resistance and maximize clinical benefit. Patients with advanced NSCLC can achieve excellent tumor control after a period of EGFR-TKI treatment. Patients may benefit from additional local treatment, such as surgery or radiation therapy, once the tumor is under control. Here, we present a case of a patient with advanced oligometastatic NSCLC with EGFR mutations who achieved downstaging through sequential EGFR-TKI-based precision medicine allowing resection of residual disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungProtein Kinase InhibitorsErbB ReceptorsLung NeoplasmsHumansMaleMiddle AgedMutationNeoplasm MetastasisFemaleAgedTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

EGFR L718Qdownstagingoligometastatic NSCLCwhole course medical management

Substanzen

Protein Kinase InhibitorsErbB ReceptorsEGFR protein, humanTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Thoracic Surgery Department, Air Force Medical Center, PLA, Beijing, People's Republic of China.
  • Medical Oncology Department, Air Force Medical Center, PLA, Beijing, People's Republic of China.
  • Anesthesiology Department, Air Force Medical Center, PLA, Beijing, People's Republic of China.
  • The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, Jiangsu Province, People's Republic of China.

Förderung

  • Wu Jieping Medical Foundation

Zitieren

APA

Wang, H., Fan, Z., Yang, X., Wu, Q., Jiang, S., Zhu, J., Liu, J., Zhou, C., Liu, Y., You, X., & Han, Y. (2024). Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non–Small Cell Lung Cancer: A Case Report. The Oncologist. https://doi.org/10.1093/oncolo/oyad339

Vancouver

Wang H, Fan Z, Yang X, Wu Q, Jiang S, Zhu J, et al. Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non–Small Cell Lung Cancer: A Case Report. The Oncologist. 2024. doi:10.1093/oncolo/oyad339

BibTeX
@article{Wang2024,
  author = {Wang, Huaiyu and Fan, Zaiwen and Yang, Xiaoming and Wu, Qing and Jiang, Suxin and Zhu, Jingna and Liu, Jie and Zhou, Chuanhong and Liu, Yinghui and You, Xia and Han, Yong},
  title = {Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non–Small Cell Lung Cancer: A Case Report},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyad339}
}
Kostenlos starten →